Q3 Earnings Forecast for Illumina Issued By Leerink Partnrs

Key Points

• Leerink Partners has increased Illumina's Q3 2025 EPS estimate from $1.18 to $1.19, reflecting a positive outlook for the company's future earnings.
• The consensus estimate for Illumina's current full-year earnings is $4.51 per share, with projections for FY2025 earnings at $4.52 EPS and FY2026 earnings at $4.93 EPS.
• Illumina's latest quarterly earnings report showed an EPS of $1.19, beating expectations, but the company's revenue was down 4.8% year-over-year.

Illumina, Inc. (NASDAQ:ILMN - Free Report) - Equities researchers at Leerink Partnrs increased their Q3 2025 EPS estimates for Illumina in a report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will earn $1.19 per share for the quarter, up from their prior estimate of $1.18. The consensus estimate for Illumina's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina's FY2025 earnings at $4.52 EPS, Q3 2026 earnings at $1.28 EPS, FY2026 earnings at $4.93 EPS and FY2027 earnings at $6.05 EPS.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the business earned $0.36 earnings per share. The firm's revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS.

Several other equities research analysts also recently issued reports on ILMN. Robert W. Baird increased their price objective on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. Canaccord Genuity Group raised their price target on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Stephens set a $110.00 price objective on Illumina and gave the stock an "overweight" rating in a report on Monday, August 4th. Finally, Daiwa America downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Illumina currently has a consensus rating of "Hold" and an average target price of $123.56.

Illumina Stock Performance

Shares of Illumina stock opened at $91.00 on Wednesday. Illumina has a 12 month low of $68.70 and a 12 month high of $156.66. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The stock has a market cap of $13.99 billion, a PE ratio of 11.52, a price-to-earnings-growth ratio of 2.29 and a beta of 1.40. The business has a fifty day simple moving average of $98.13 and a 200-day simple moving average of $90.43.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Diversified Trust Co acquired a new position in Illumina during the 1st quarter valued at $355,000. Bourgeon Capital Management LLC increased its holdings in shares of Illumina by 76.4% during the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company's stock worth $13,538,000 after purchasing an additional 61,468 shares during the period. GC Wealth Management RIA LLC acquired a new position in shares of Illumina during the second quarter valued at about $2,289,000. State of Alaska Department of Revenue lifted its stake in shares of Illumina by 2.5% in the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock valued at $1,469,000 after buying an additional 445 shares during the period. Finally, waypoint wealth counsel acquired a new stake in Illumina during the second quarter worth about $321,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.